Investing.com - Mesoblast (NASDAQ: MESO) reported second quarter EPS of $-0.166, $0.01 better than the analyst estimate of $-0.180. Revenue for the quarter came in at $2.13M versus...
Mesoblast (NASDAQ:MESO) Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced publication of the DREAM-HF Phase...
Novartis NVS and partner Incyte (NASDAQ:INCY) INCY announced that the late-stage study on ruxolitinib in COVID-19 patients was not successful.The phase III RUXCOVID study is a...
This week, the biotech sector was in focus with updates from biotechs evaluating their pipeline drugs and vaccines for the treatment of COVID-19. A new strain of coronavirus, which...
For Immediate ReleaseChicago, IL – January 20, 2020 – Stocks in this week’s article are China Distance Education Holdings Ltd. (NYSE:DL) , Intellicheck...
Mesoblast Limited is an Australia-based company that is engaged in the development of regenerative medicine products. The Company’s primary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It has applied its mesenchymal lineage cell technology platform to the allogeneic cellular medicines portfolio in the industry. Its technology addresses multiple inflammatory conditions with unmet medical needs. The Company’s portfolio of Phase III product candidates comprises remestemcel-L for steroid-refractory acute graft versus host disease (acute GVHD), as well as for the treatment of moderate to severe acute respiratory distress syndrome (ARDS) due to COVID-19 infection, Revascor for advanced chronic heart failure and MPC-06-ID for chronic low back pain due to degenerative disc disease. The Company’s subsidiaries include Mesoblast, Inc., Mesoblast International Sarl, Mesoblast Australia Pty Ltd, Mesoblast UK Ltd and BeiCell Ltd.
| Average | 10.625 (+243.851% Upside) |
| High | 23.000 |
| Low | 2.500 |
| Price | 3.090 |
| No. of Analysts | 5 |
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Strong Sell |
| Technical Indicators | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Strong Sell |
| Summary | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Strong Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 190.41 | 192.36 | 187.15 | -1.81 | -0.94% | 115.62M | NASDAQ | |||
| 160.25 | 160.34 | 157.85 | +1.32 | +0.83% | 56.97M | NASDAQ | |||
| 60.90 | 61.01 | 59.91 | +0.98 | +1.64% | 12.65M | NYSE | |||
| 206.01 | 207.58 | 203.55 | +1.73 | +0.85% | 27.63M | NASDAQ | |||
| 105.44 | 105.49 | 103.84 | -0.16 | -0.15% | 30.02M | NASDAQ | |||
| 280.57 | 280.63 | 275.28 | +2.91 | +1.05% | 28.01M | NASDAQ | |||
| 40.39 | 40.46 | 39.87 | +0.21 | +0.52% | 17.13M | NYSE | |||
| 97.95 | 99.52 | 96.74 | -2.33 | -2.32% | 64.14M | NASDAQ | |||
| 98.13 | 98.30 | 96.40 | -0.58 | -0.59% | 55.74M | NASDAQ | |||
| 156.56 | 158.27 | 153.56 | -3.42 | -2.14% | 2.51M | NASDAQ | |||
| 267.79 | 271.67 | 263.55 | -4.12 | -1.52% | 45.08M | NASDAQ | |||
| 8.20 | 8.35 | 8.06 | -0.13 | -1.56% | 17.94M | NYSE | |||
| 106.07 | 106.16 | 104.74 | -0.18 | -0.17% | 25.05M | NASDAQ | |||
| 44.98 | 45.58 | 44.24 | -0.81 | -1.77% | 11.16M | NYSE | |||
| 50.51 | 50.55 | 49.49 | +0.78 | +1.57% | 19.26M | NASDAQ |